188 related articles for article (PubMed ID: 16156659)
21. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y; Shai Y
J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
[TBL] [Abstract][Full Text] [Related]
22. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
Miyauchi K; Kozlov MM; Melikyan GB
PLoS Pathog; 2009 Sep; 5(9):e1000585. PubMed ID: 19763181
[TBL] [Abstract][Full Text] [Related]
23. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
25. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
27. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.
Kilgore NR; Salzwedel K; Reddick M; Allaway GP; Wild CT
J Virol; 2003 Jul; 77(13):7669-72. PubMed ID: 12805467
[TBL] [Abstract][Full Text] [Related]
28. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
29. The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.
Huang JH; Yang HW; Liu S; Li J; Jiang S; Chen YH
Biochem J; 2007 May; 403(3):565-71. PubMed ID: 17223796
[TBL] [Abstract][Full Text] [Related]
30. Identification of membrane-active regions of the HIV-1 envelope glycoprotein gp41 using a 15-mer gp41-peptide scan.
Moreno MR; Pascual R; Villalaín J
Biochim Biophys Acta; 2004 Feb; 1661(1):97-105. PubMed ID: 14967479
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.
Chen CH; Greenberg ML; Bolognesi DP; Matthews TJ
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2037-41. PubMed ID: 11153086
[TBL] [Abstract][Full Text] [Related]
32. Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function.
Bellamy-McIntyre AK; Bär S; Ludlow L; Drummer HE; Poumbourios P
Biochem Biophys Res Commun; 2010 Apr; 394(4):904-8. PubMed ID: 20230797
[TBL] [Abstract][Full Text] [Related]
33. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide.
Weissenhorn W; Wharton SA; Calder LJ; Earl PL; Moss B; Aliprandis E; Skehel JJ; Wiley DC
EMBO J; 1996 Apr; 15(7):1507-14. PubMed ID: 8612573
[TBL] [Abstract][Full Text] [Related]
34. The mechanism of inhibition of HIV-1 env-mediated cell-cell fusion by recombinant cores of gp41 ectodomain.
Markosyan RM; Ma X; Lu M; Cohen FS; Melikyan GB
Virology; 2002 Oct; 302(1):174-84. PubMed ID: 12429526
[TBL] [Abstract][Full Text] [Related]
35. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.
Jiang S; Lin K; Zhang L; Debnath AK
J Virol Methods; 1999 Jun; 80(1):85-96. PubMed ID: 10403680
[TBL] [Abstract][Full Text] [Related]
36. Membrane-perturbing domains of HIV type 1 glycoprotein 41.
Mobley PW; Pilpa R; Brown C; Waring AJ; Gordon LM
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):311-27. PubMed ID: 11242518
[TBL] [Abstract][Full Text] [Related]
37. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
38. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein.
Lu M; Kim PS
J Biomol Struct Dyn; 1997 Dec; 15(3):465-71. PubMed ID: 9439994
[TBL] [Abstract][Full Text] [Related]
39. Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action.
Lev N; Fridmann-Sirkis Y; Blank L; Bitler A; Epand RF; Epand RM; Shai Y
Biochemistry; 2009 Apr; 48(14):3166-75. PubMed ID: 19206186
[TBL] [Abstract][Full Text] [Related]
40. Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.
Jin BS; Ryu JR; Ahn K; Yu YG
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1797-804. PubMed ID: 11118065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
